Aberdeen Group plc Grows Stock Position in Zoetis Inc. $ZTS

Aberdeen Group plc boosted its stake in Zoetis Inc. (NYSE:ZTS) by 5.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,155,604 shares of the company’s stock after acquiring an additional 59,245 shares during the quarter. Aberdeen Group plc’s holdings in Zoetis were worth $179,720,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Nuveen LLC purchased a new position in Zoetis in the 1st quarter worth approximately $616,375,000. Mackenzie Financial Corp boosted its holdings in Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after acquiring an additional 1,782,110 shares during the period. Polen Capital Management LLC boosted its stake in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after buying an additional 1,313,653 shares during the last quarter. Amundi boosted its stake in shares of Zoetis by 30.8% during the 1st quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after buying an additional 846,909 shares during the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its stake in shares of Zoetis by 475.9% in the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock worth $148,228,000 after buying an additional 743,926 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $141.05 on Friday. The business’s fifty day moving average price is $149.24 and its 200 day moving average price is $154.46. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $196.55. The stock has a market capitalization of $62.51 billion, a PE ratio of 24.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period last year, the business posted $1.56 earnings per share. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is currently 34.42%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ZTS shares. Argus reiterated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and reduced their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $196.71.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.